[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neumora Therapeutics Inc (NMRA)

Neumora Therapeutics Inc (NMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 302,013
  • Shares Outstanding, K 185,284
  • Annual Sales, $ 0 K
  • Annual Income, $ -236,930 K
  • EBIT $ -223 M
  • EBITDA $ -225 M
  • 60-Month Beta 2.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.24

Options Overview Details

View History
  • Implied Volatility 340.18% (-217.03%)
  • Historical Volatility 56.48%
  • IV Percentile 96%
  • IV Rank 57.39%
  • IV High 557.21% on 08/07/26
  • IV Low 47.87% on 09/03/25
  • Expected Move (DTE 11) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 66
  • Volume Avg (30-Day) 995
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 28,270
  • Open Int (30-Day) 37,838
  • Expected Range 1.6200 to 1.6200

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 4
  • High Estimate $-0.20
  • Low Estimate $-0.30
  • Prior Year $-0.33
  • Growth Rate Est. (year over year) +30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4600 +10.96%
on 07/24/26
1.7200 -5.81%
on 07/17/26
-0.0600 (-3.57%)
since 07/10/26
3-Month
0.8302 +95.13%
on 06/15/26
1.9850 -18.39%
on 05/14/26
-0.2100 (-11.48%)
since 05/08/26
52-Week
0.8302 +95.13%
on 06/15/26
3.6500 -55.62%
on 02/18/26
+0.1600 (+10.96%)
since 08/08/25

Most Recent Stories

More News
Neumora: Can Restarted Trials Justify Cash Runway Through Mid-Year Only?

Barchart Research What to Expect from NMRA Earnings NMRA Generated August 4, 2026 Current Price $1.6000 EPS Estimate $$-0.23 Consensus Rating Moderate Buy Average Move 8.92% Neumora: Can Restarted Trials...

NMRA : 1.6200 (-0.61%)
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...

NMRA : 1.6200 (-0.61%)
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

Neumora Therapeutics projected cash runway "into 2027" tied to clinical milestones that never materialized -- then cut 35% of its workforce the same day both pivotal trials failed.

NMRA : 1.6200 (-0.61%)
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

Neumora Therapeutics characterized its first failed Phase 3 trial as an "anomaly" and projected 90% statistical power across its navacaprant program -- then both remaining pivotal trials failed, triggering...

NMRA : 1.6200 (-0.61%)
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%.

NMRA : 1.6200 (-0.61%)
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease...

NMRA : 1.6200 (-0.61%)
SoftBank Just Dumped Circle Stock. Don’t Panic and Keep Adding CRCL Here.

SoftBank fully exited Circle Internet Group in Q1 2026. Here is what investors need to know about the stablecoin giant's fundamentals.

TMUS : 178.20 (+0.57%)
BLK : 1,131.40 (-0.44%)
META : 594.92 (+0.48%)
LMND : 52.68 (-0.49%)
CRCL : 67.05 (+0.57%)
SFTBY : 16.7600 (-4.77%)
NMRA : 1.6200 (-0.61%)
ICE : 150.54 (+0.16%)
^USDCUSD : 0.999950 (unch)
UBER : 78.03 (+4.01%)
DASH : 209.86 (-2.96%)
LIFE : 32.43 (+2.59%)
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...

NMRA : 1.6200 (-0.61%)
Neumora's Pipeline Credibility Rests on Two Readouts Due Within Weeks

Barchart Research What to Expect from NMRA Earnings NMRA Generated May 8, 2026 Current Price $1.8300 EPS Estimate $$-0.25 Consensus Rating Moderate Buy Average Move 7.45% Neumora's Pipeline Credibility...

NMRA : 1.6200 (-0.61%)
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation...

NMRA : 1.6200 (-0.61%)

Business Summary

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora...

See More

Key Turning Points

3rd Resistance Point 1.7533
2nd Resistance Point 1.7067
1st Resistance Point 1.6633
Last Price 1.6200
1st Support Level 1.5733
2nd Support Level 1.5267
3rd Support Level 1.4833

See More

52-Week High 3.6500
Fibonacci 61.8% 2.5728
Fibonacci 50% 2.2401
Fibonacci 38.2% 1.9074
Last Price 1.6200
52-Week Low 0.8302

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.